Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BILR 355 BS in Healthy Males
NCT02254538Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2002
- Primary completion
- Feb 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus type 1 infection (HIV-1) comparing BILR 355 BS with Placebo (2 arms). Primary endpoints: Number of participants with clinically significant changes in vital functions at 10 days, Number of participants with abnormal findings in ECG at 10 days and 5 more. Started May 2002; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02254538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254538.